StockNews.AI
ALGS
StockNews.AI
105 days

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

1. Aligos raised over $100M for phase 2 study of ALG-000184. 2. ALG-000184 shows potential as first-line treatment for chronic HBV infection. 3. ALG-055009 demonstrated significant liver fat reduction in phase 2a study. 4. Cash and investments increased to $137.9M as of March 31, 2025. 5. Aligos is on track for phase 2 clinical study data release in 2026.

15m saved
Insight
Article

FAQ

Why Bullish?

Strong financial position and positive trial data indicate growth potential. Historical data shows positive price movements after funding announcements.

How important is it?

Raising substantial funds and showing positive trial results are pivotal for market confidence. This significantly influences investor sentiment and stock valuation.

Why Long Term?

Upcoming phase 2 results and market potential for therapies may take time to materialize. Similar companies have seen delayed revenue realization from clinical studies.

Related Companies

GILDINCYVRTXREGNAMGN
May 06, 2025 08:00 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025. “We continued to make progress towards our corporate development plans aimed at advancing life-saving therapies for viral and liver diseases,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “Over the past few months, we raised over $100M to begin our important Phase 2 study of ALG-000184 in chronic hepatitis B virus infection and we are on track to begin dosing by mid-2025 following recent positive correspondence with the FDA. Our data presentation at the APASL meeting showcased the extension of dosing to 96 weeks. These data continue to support our belief that ALG-000184 has the potential to be first line standard of care treatment for chronic suppression of HBV infection as well as the drug of choice to combine with other agents aimed at functional cure. Additionally, recent data presented at the APASL meeting for ALG-055009, our THR-β agonist for the treatment of MASH, further demonstrated best-in-class potential. We are continuing our partnering discussions for ALG-055009 with several multinational pharmaceutical companies that have strong interests in MASH and other metabolic diseases.”  Recent Business Progress Pipeline Updates ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection 96-week dosing recently completed in the Phase 1 study and data readouts are planned for scientific conferences this yearInterim data from up to 96 weeks following an oral daily dose of 300 mg ALG-000184 in both HBeAg+ and HBeAg- subjects with chronic HBV infection were presented at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025 ALG-000184 administered for up to 96 weeks was well tolerated, exhibited a favorable PK profile, and demonstrated potentially best-in-class antiviral activityData from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (

Related News